174 related articles for article (PubMed ID: 31162838)
61. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Rinnerthaler G; Gampenrieder SP; Petzer A; Burgstaller S; Fuchs D; Rossmann D; Balic M; Egle D; Rumpold H; Singer CF; Bartsch R; Petru E; Melchardt T; Ulmer H; Mlineritsch B; Greil R
BMC Cancer; 2018 Nov; 18(1):1074. PubMed ID: 30400780
[TBL] [Abstract][Full Text] [Related]
62. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
Jiang T; Shi W; Wali VB; Pongor LS; Li C; Lau R; Győrffy B; Lifton RP; Symmans WF; Pusztai L; Hatzis C
PLoS Med; 2016 Dec; 13(12):e1002193. PubMed ID: 27959926
[TBL] [Abstract][Full Text] [Related]
63. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
64. Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer.
Palazzo A; Dellapasqua S; Munzone E; Bagnardi V; Mazza M; Cancello G; Ghisini R; Iorfida M; Montagna E; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2018 Aug; 18(4):328-335. PubMed ID: 29486983
[TBL] [Abstract][Full Text] [Related]
65. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
Osborne C; Challagalla JD; Eisenbeis CF; Holmes FA; Neubauer MA; Koutrelakos NW; Taboada CA; Vukelja SJ; Wilks ST; Allison MA; Reddy P; Sedlacek S; Wang Y; Asmar L; O'Shaughnessy J
Clin Breast Cancer; 2018 Feb; 18(1):e89-e95. PubMed ID: 28779904
[TBL] [Abstract][Full Text] [Related]
66. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
[TBL] [Abstract][Full Text] [Related]
67. Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer.
Yardley DA; Shipley DL; Peacock NW; Shastry M; Midha R; Priego VM; Hainsworth JD
Breast Cancer Res Treat; 2015 Aug; 152(3):557-67. PubMed ID: 26155975
[TBL] [Abstract][Full Text] [Related]
68. A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.
Zhu T; Liu CL; Zhang YF; Liu YH; Xu FP; Zu J; Zhang GC; Li XR; Liao N; Wang K
Breast Cancer Res Treat; 2016 Feb; 156(1):117-24. PubMed ID: 26936755
[TBL] [Abstract][Full Text] [Related]
69. Expression of organic anion-transporting polypeptide 1A2 and organic cation transporter 6 as a predictor of pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.
Hashimoto Y; Tatsumi S; Takeda R; Naka A; Ogane N; Kameda Y; Kawachi K; Shimizu S; Sakai M; Kamoshida S
Breast Cancer Res Treat; 2014 May; 145(1):101-11. PubMed ID: 24671357
[TBL] [Abstract][Full Text] [Related]
70. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Lynce F; Stevens LE; Li Z; Brock JE; Gulvady A; Huang Y; Nakhlis F; Patel A; Force JM; Haddad TC; Ueno N; Stearns V; Wolff AC; Clark AS; Bellon JR; Richardson ET; Balko JM; Krop IE; Winer EP; Lange P; Hwang ES; King TA; Tolaney SM; Thompson A; Gupta GP; Mittendorf EA; Regan MM; Overmoyer B; Polyak K
Breast Cancer Res; 2024 Jan; 26(1):20. PubMed ID: 38297352
[TBL] [Abstract][Full Text] [Related]
71. Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial.
Freitas AJA; Nunes CR; Mano MS; Causin RL; Santana IVV; de Oliveira MA; Calfa S; Silveira HCS; de Pádua Souza C; Marques MMC
Sci Rep; 2023 Dec; 13(1):21411. PubMed ID: 38049525
[TBL] [Abstract][Full Text] [Related]
72. A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.
Pérez-Pena J; Tibor Fekete J; Páez R; Baliu-Piqué M; García-Saenz JÁ; García-Barberán V; Manzano A; Pérez-Segura P; Esparis-Ogando A; Pandiella A; Gyorffy B; Ocana A
Front Immunol; 2019; 10():2802. PubMed ID: 31921107
[TBL] [Abstract][Full Text] [Related]
73. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.
Kuemmel S; Campone M; Loirat D; Lopez RL; Beck JT; De Laurentiis M; Im SA; Kim SB; Kwong A; Steger GG; Adelantado EZ; Duhoux FP; Greil R; Kuter I; Lu YS; Tibau A; Özgüroğlu M; Scholz CW; Singer CF; Vega E; Wimberger P; Zamagni C; Couillebault XM; Fan L; Guerreiro N; Mataraza J; Sand-Dejmek J; Chan A
Clin Cancer Res; 2022 Jan; 28(1):106-115. PubMed ID: 34615719
[TBL] [Abstract][Full Text] [Related]
74. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.
Picornell AC; Echavarria I; Alvarez E; López-Tarruella S; Jerez Y; Hoadley K; Parker JS; Del Monte-Millán M; Ramos-Medina R; Gayarre J; Ocaña I; Cebollero M; Massarrah T; Moreno F; García Saenz JA; Gómez Moreno H; Ballesteros A; Ruiz Borrego M; Perou CM; Martin M
BMC Genomics; 2019 Jun; 20(1):452. PubMed ID: 31159741
[TBL] [Abstract][Full Text] [Related]
75. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC.
Massa C; Karn T; Denkert C; Schneeweiss A; Hanusch C; Blohmer JU; Zahm DM; Jackisch C; van Mackelenbergh M; Thomalla J; Marme F; Huober J; Müller V; Schem C; Mueller A; Stickeler E; Biehl K; Fasching PA; Untch M; Loibl S; Weber K; Seliger B
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199511
[TBL] [Abstract][Full Text] [Related]
76. Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel.
Lang JD; Nguyen TVV; Levin MK; Blas PE; Williams HL; Rodriguez ESR; Briones N; Mueller C; Selleck W; Moore S; Zismann VL; Hendricks WPD; Espina V; O'Shaughnessy J
Biomark Res; 2023 Jul; 11(1):73. PubMed ID: 37491309
[TBL] [Abstract][Full Text] [Related]
77. Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice.
O'Shaughnessy J; Emens LA; Chui SY; Wang W; Russell K; Lin SW; Flores Avile C; Luhn P; Schneeweiss A
Curr Oncol; 2021 Jul; 28(4):2741-2752. PubMed ID: 34287291
[TBL] [Abstract][Full Text] [Related]
78. PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts.
Kensler KH; Sankar VN; Wang J; Zhang X; Rubadue CA; Baker GM; Parker JS; Hoadley KA; Stancu AL; Pyle ME; Collins LC; Hunter DJ; Eliassen AH; Hankinson SE; Tamimi RM; Heng YJ
Cancer Epidemiol Biomarkers Prev; 2019 Apr; 28(4):798-806. PubMed ID: 30591591
[TBL] [Abstract][Full Text] [Related]
79. The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy.
Nakazawa Y; Nakazawa S; Kurozumi S; Ogino M; Koibuchi Y; Odawara H; Oyama T; Horiguchi J; Fujii T; Shirabe K
Oncol Lett; 2020 Apr; 19(4):2705-2712. PubMed ID: 32218821
[TBL] [Abstract][Full Text] [Related]
80. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).
Liu MC; Pitcher BN; Mardis ER; Davies SR; Friedman PN; Snider JE; Vickery TL; Reed JP; DeSchryver K; Singh B; Gradishar WJ; Perez EA; Martino S; Citron ML; Norton L; Winer EP; Hudis CA; Carey LA; Bernard PS; Nielsen TO; Perou CM; Ellis MJ; Barry WT
NPJ Breast Cancer; 2016; 2():15023-. PubMed ID: 28691057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
